studies

mGC or mGEJC - M - HER2 neg/PDL1 positive, immune chekpoint inhibitors vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsJAVELIN Gastric 100 (PDL1>1%), 2020 1.13 [0.57; 2.24] 1.13[0.57; 2.24]JAVELIN Gastric 100 (PDL1>1%), 202010%54NAnot evaluable progression or deaths (PFS)detailed resultsJAVELIN Gastric 100 (PDL1>1%), 2020 1.04 [0.53; 2.03] 1.04[0.53; 2.03]JAVELIN Gastric 100 (PDL1>1%), 202010%54NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-05-15 20:16 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 304 - treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,854,374,1073,953,672,1080,862,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,746,745,856,634,861,416,864,769,980,369,743